Introduction Introduction
The incidence of complete Achilles tendon rupture is 18 per 100 000 patient-years 1 and is usually diagnosed clinically by GPs. The extent of clinical misdiagnosis is unknown in Norway, but may be high. 2 This is important as delayed treatment has unfavourable consequences. 1, 3 We report how a GP, with no clinical ultrasound experience, recorded images with a pocket-sized ultrasound device (PSUD) under supervision to confirm a complete Achilles tendon rupture. This could present a new indication for GP ultrasound.
Case report
A 36-year-old man experienced acute pain above the right heel accompanied by an audible snap while sprinting. He immediately had difficulty walking and 3 hours later consulted an on-call GP. Posterior ankle swelling with a tender depression 3 cm proximal to the calcaneum was found. Active plantar flexion against resistance was weak and Simmonds-Thompson test was 'partially positive' on applying a strong calf-squeeze. Based on these findings, calf muscle rupture was diagnosed as the Achilles tendon was thought to be intact. The patient was advised to elevate the foot and wait 2 weeks for improvement. Two days later a second GP, who was aware of a history of an audible snap, considered complete tendon rupture and reexamined the patient. Findings included an absent right heel raise due to weakness, minimal active plantar flexion against gravity and lying prone, significant right ankle swelling without bruising, and an altered angle of declination. Palpation elicited no ankle bony tenderness, yet a painful gap was identified 6 cm proximal from the calcaneal attachment, along the line of the Achilles tendon. Simmonds-Thompson's test was clearly positive. The positive Simmond's triad indicated a clinical diagnosis of complete rupture of the Achilles tendon. A 3.4-8 MHz linear array probe PSUD (VScanÔ dual probe, GE Healthcare), set at a depth of 3.5 cm, was used under the supervision of a rheumatologist experienced in ultrasound. The tendon was enlarged from 1 cm to 6 cm above the calcaneal insertion, where a clear gap was seen ( Figure 1) . Two hours later a radiologist-performed ultrasound (LOGIQ E9Ô, GE Healthcare) and reported an enlarged distal tendon and a complete rupture at 5-6 cm from the calcaneal attachment, creating a 2.7 cm blood-filled gap ( Figure 2 ). Surgical exploration 8 days post-injury found a complete Achilles tendon rupture '5-10 cm above the ankle joint'.
Discussion
Tromsø Hospital serves a large area with a population of approximately 160 000. Between 2010-2014 an average of 21 patients per year were referred by their GP for suspected Achilles rupture.
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Introduction
Last summer our small medical team visited the Calais 'Jungle'. Since that time much has changed and the camp is being demolished and by the time this article is read, it will probably be long gone. Some youngsters are finally being brought to the UK under the 'Dubs' amendment. However, once this camp is cleared it will not solve the ongoing flight of refugees from war torn areas: other camps are already appearing.
July 2016
A young Afghan man caught his finger on a sharp point while trying to cross a barbed wire fence. The finger was partially degloved. He attended the local hospital, where they placed a few sutures, but now, 2 weeks later, the skin is necrotic and the underlying tissue looks infected. He is in danger of losing his finger. A middle-aged Sudanese man has been having rigors and is generally unwell. He says it is similar to when he last had malaria.
A young Ukrainian woman complains of lower back pain and urinary frequency. The paths of these three people may never have crossed; yet here they are, denizens of the Calais Jungle. They turn up to a makeshift primary care 'clinic' that we set up in the heart of the unofficial refugee camp one weekend in July 2016.
With only basic medical supplies, we are immediately challenged by what we see. How can we arrange secondary care for the young Afghan in danger of losing his finger? We try to persuade him to return to the original local hospital, but he is reluctant. It was not a good experience for him the first time round.
With the other two patients, it is easier. They can attend the Salam clinic run by a local association during weekdays. Later, we receive word that malaria has been confirmed in our Sudanese patient.
More people arrive, presenting with scabies, rat bites, tinea, chest infections, and wheezing from inhaling smoke from fires lit to cook and keep warm in their tents at night. We examine a severely malnourished 2-year-old boy. We meet several of the camp's 600 unaccompanied children, at grave risk of sexual exploitation. We learn that there is inadequate safeguarding in place to protect them. A young Eritrean man comes in worried about his eye. He has sustained direct ocular trauma from a rubber bullet, and will never see normally again out of that eye. We see haematomas from police batons, and hear about children being exposed to tear gas again and again ( Figure 1 ).
The reality
These are no ordinary patients. They have travelled far from home to escape war, poverty, and misery. They have endured personal odysseys to get here, experienced untold hardships, and suffered unimaginable privations. Many have survived the loss of their families, torture, and rape. Their journeys over, for the moment at least, they must make their homes in the Calais Jungle. Their new shelters are in many cases mere tarpaulin covers, and their new beds just rugs on the ground. They own next to nothing. There is little for them to do, besides use their ingenuity to cross the English Channel in search of a better life. They are vulnerable to exploitation, crime, injury, and disease. Potentially violent clashes with local police, with other ethnic groups resident in the Jungle, or local far suggest that general practice visitation and prescribing rates should be higher for people with ID than for the general population. In line with this supposition, Straetmans and colleagues 9 used data from the Second Dutch National Survey of General Practice to determine that people with ID visited GPs more frequently than matched controls, and received more repeat prescriptions. However, somewhat surprisingly, per consultation they reported that people with ID were less likely to receive a prescription. A recently published analysis from the Australian BEACH data set also reported the surprising finding that fewer overall medication recommendations were made at ID general practice encounters. 8 Neither Straetmans 9 nor Weise 8 reported prescription rates by medication class or group. There is therefore a need to clarify which, if any, types of medications may be under-or overprescribed to people with ID in general practice. Such an analysis may help to inform future general practice education.
The BEACH programme provides a mechanism to explore and compare nationally representative primary care medication data for face-to-face and phone encounters between GPs and patients at which ID is recorded ('ID group') versus other ('non-ID group') encounters. Through analysis of the BEACH dataset, this study addresses the research question: do the types of medication recommended at ID group encounters differ from those at non-ID group encounters? The authors hypothesised that the types of medications recommended at ID group encounters would differ from those at non-ID group encounters, according to known patterns of medical and psychiatric comorbidities experienced by people with ID. Research details of 100 consecutive encounters with consenting, de-identified patients on structured paperbased forms. Carers are able to consent on behalf of patients who lack capacity to self-consent. RFEs and problems managed are secondarily coded in the Australian general practice terminology known as ICPC-2 PLUS, 11,12 which is classified according to the International Classification of Primary Care (ICPC-2). Participating GPs are asked to record at least one, and up to four, problems managed at the encounter, with a maximum of four medications recorded per problem, and to indicate whether each of these medications was 'prescribed', 'GP-supplied', or 'recommended for over the counter purchase'. For the purposes of this report, these medication pathways are collectively referred to as medications 'recommended' by the GP. An in-house BEACH system, the Coding Atlas for Pharmaceutical Substances (CAPS) is used to classify all recorded medications based on anatomical site and therapeutic use. CAPS allows analysis at the group, sub-group, generic (composition of drug), proprietary brand name, product, and form levels. This paper reports on medication recommendations at the CAPS group, sub-group, and generic levels. While medications in the CAPS coding system are mapped to the Anatomical Therapeutic Chemical (ATC) classification, the CAPS system provided greater specificity than the ATC equivalent in certain cases. For example, at the CAPS group level, 'psychological' medications can be analysed separately from 'central nervous system (CNS)' medications, whereas the ATC level 1 equivalent 'nervous system' category does not provide this specificity. In order to maximise the clinical utility of the data, this study therefore reports medication findings according to the CAPS classification.
Any encounter where 1 ID-defining problem was recorded as a patient RFE and/or as a problem managed at encounter was defined as an 'ID group' encounter. The ID-defining RFEs and problems were all those classified in ICPC-2 as 'P85 mental retardation', and selected ICPC-2 PLUS codes forming part of ICPC-2 'A90 congenital anomaly not otherwise specified/multiple', namely A90001 (Down syndrome) and A90015 (Fragile X syndrome). All other encounters that occurred during the study timeframe were defined as non-ID group encounters. By implication, all patients at ID group encounters had, or were being assessed for, a diagnosis of ID. Although it is likely that a small proportion of encounters in the non-ID group were with patients with ID, the large size of this group would mean that the inadvertent inclusion of these individuals in the non-ID group would have minimal impact on results. Medication recommendations made at ID group and at non-ID group encounters were compared.
Statistical analysis
A single-stage cluster design is used in the BEACH programme and all analyses are adjusted for clustering (at the level of participating GP).
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The c 2 test was used to determine the statistical significance of demographic differences between patients in the ID group and the non-ID group. To allow for meaningful between-group comparisons, data at ID group encounters were weighted to model the results expected if the age-sex distribution of patients at ID group encounters was matched to that at non-ID group encounters ('agesex standardisation'). The rates of recommendation of medications per 100 encounters were analysed at the CAPS group, sub-group, and generic medication level, and the ID group and non-ID group were compared. Between-group differences were considered significant if there was no overlap in the 95% CIs. This is equivalent to P<0.006 13 for each comparison, which is more conservative than the usual P<0.05. The statistical software package SAS (version 9.3) was used.
Results

Patient demographics
Of a total of 971 331 BEACH encounters with a specified patient age, 690 (0.07%) were classed as ID encounters. The age and sex distribution of patients differed between the ID group and non-ID group, the ID group having over-representation of patients aged 5-44 years, and of males ( Table 1) .
The over-representation of males at ID group encounters may be partially explained by the higher incidence of ID in men compared to women. 14 There were 563 medications recommended at ID group encounters and 1 004 095 at non-ID group encounters.
Medication 'group' recommendations (CAPS 'group' level)
All results are presented as medications per 100 encounters, with 95% CIs. Medication 'subgroup' recommendations (CAPS 'subgroup' level) 
Psychoactive medication subgroup recommendations
Anticonvulsants and antipsychotics were recommended significantly more often at ID group encounters compared with non-ID group encounters ( Table 3) . There was no difference in recommendation rates for antidepressant, anti-anxiety, and sedative or hypnotic medication subgroups.
Analgesic subgroup prescriptions
There was no difference between the ID and non-ID groups in the recommendation rate of simple analgesics, but recommendations of narcotic analgesics at ID group encounters was significantly lower than at non-ID group encounters ( 
Individual medication recommendations (CAPS 'generic medication' level)
Compared with non-ID group encounters, the following medications were recommended significantly more often to patients at ID group encounters: sodium valproate (2.9 [95% CI = 1.0 to 4.8] 
Discussion Summary
Analysis of data from a large national primary care database revealed significant between-group prescribing differences at the CAPS medication group, sub-group, and generic medication level. Narcotic analgesics and cardiovascular system medications such as antihypertensives were recommended at significantly lower rates at ID group encounters. However, nervous system medications, specifically antipsychotics and anticonvulsants, were recommended at higher rates at ID group encounters.
Strengths and limitations
The strengths of this study include the robust BEACH programme methodology that allows for collection of continuous cross-sectional primary care medication data. This is the only Australian data a Non-overlapping 95% confidence intervals, comparing age-sex standardised ID with non-ID group. ID = intellectual disability. NSAID = non-steroidal anti-inflammatory drug. set that allows comparison of national GP medication recommendations at ID and non-ID encounters. However, there are a number of limitations to consider when interpreting study results. Firstly, caution is urged when interpreting results, in view of wide confidence intervals. Secondly, it is likely that ID encounters are under-represented in this data set. For example, at encounters where the person with ID was unable to provide consent and did not have a carer present, the GP would not have included the encounter record as per the BEACH ethics protocol. Some genetic syndromes that have variable association with ID, for example tuberous sclerosis, were also excluded from the coding structure so as to avoid inadvertently including people in the ID group who did not have ID.
Thirdly, presence or absence of ID was not collected as part of the patient demographic data in the BEACH programme. While all prescriptions have been allocated to the ID-group where ID was indicated as an RFE or a problem managed, it is possible that prescriptions for some people with ID may have been incorrectly allocated to the non-ID group if ID was not an RFE or a problem managed.
Comparison with previous literature
Antipsychotics and anticonvulsants were the most frequently recommended CAPS medication subgroups in ID group encounters, but only ranked 36th and 37th respectively in non-ID group encounters. Higher antipsychotic and anticonvulsant recommendations at ID group encounters in this study are consistent with previous literature. 15 Given the elevated prevalence of mental illness 16 and epilepsy 17 in people with ID, the finding that some medications used to treat these conditions are prescribed more frequently at ID group encounters is not unexpected. Previous analysis from this data set, for example, identified that epilepsy was the third most common problem managed at ID group encounters. 8 However, the significant over-representation of antipsychotic recommendations at ID group encounters may also relate to their use for behavioural control rather than for clearly defined mental illness. Despite limited evidence of efficacy 18, 19 numerous studies have demonstrated high rates of antipsychotic use in people with ID in the absence of a defined mental illness.
15,20,21
Recommendations for antidepressants and anxiolytics were no higher at ID than non-ID group encounters. This finding is somewhat surprising given well-documented links between ID and increased vulnerability to mental illness. 22 A previous analysis of the BEACH data set found depression was less likely to be recorded as a problem managed at ID group encounters. 8 It is possible that diagnostic overshadowing prevented recognition and subsequent treatment of certain mental illnesses in this sample of people with ID. Disorders that are less likely to present with severe disturbances in thoughts or behaviour, such as depression and anxiety, may be particularly challenging to diagnose in primary care. 23 It is important to note, however, that while a number of studies have indicated elevated rates of depression and/or anxiety in the ID population, 22, 24, 25 the exact point prevalence of these conditions is not known. 26 Diagnostic challenges relating to the detection of depression and anxiety in people with ID, particularly those on the severe or profound spectrum, and inconsistent methodologies applied in past epidemiological studies 26 mean further clarification of these results is needed. The lower narcotic analgesia recommendation rates at ID group encounters in this study were another surprising finding, given that a diagnosis of ID is associated with multiple co-morbidities that make the experience of acute and chronic pain more likely than in the general population. 27, 28 As noted previously, this finding should be interpreted with caution due to the relatively wide confidence intervals, although it is consistent with other literature 29, 30, 31 that raises questions about the adequacy of pharmacological pain management in people with ID. Clinicians face a number of challenges when assessing pain and analgesic treatment response in people with ID. Many patients with ID lack the ability to self-report the location and/or extent of pain, 32 or may express pain in idiosyncratic ways. 33 ID-specific pain management education and access to appropriate non-verbal modified pain scales 34 may help GPs to identify and adequately treat pain in this population.
The comparatively low rate of cardiovascular medication recommendations, particularly antihypertensives, at ID group encounters is surprising given elevated cardiovascular risk factors associated with a diagnosis of ID. 35 People with ID are prescribed antipsychotics (many of which have a high cardiometabolic liability) at greater rates, and beginning at an earlier age, than the general population. 36 They are also less likely to be physically active, 37 more likely to be overweight, 38 and more likely to experience genetic syndromes associated with elevated baseline risk.
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This study's finding of lower antihypertensive recommendations at ID group encounters is consistent with a number of earlier studies reporting under-detection and under-treatment of chronic cardiovascular health conditions in people with ID. 39 For example, nearly double the rate of missed metabolic syndrome diagnoses were reported in people with ID compared to the general population in the Dutch Healthy Ageing in Intellectual Disability study, 40 and hypertension was previously undiagnosed in 50% of the ID cases. It is possible that constraints imposed by administrative ID-associated paperwork -along with the complexity of managing multiple presenting problems simultaneously in a general practice setting 8 -mean that some clinicians may omit routine procedures such as blood pressure measurement to save time. This may, in turn, contribute to the undermanagement of hypertension in this population. GPs may also have fewer opportunities to assess the cardiometabolic health of their clients since low levels of health literacy among people with ID mean that as a group they are less likely to present spontaneously to their GP for preventative physical health care.
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Implications for research and practice
This analysis does not examine reasons for differences in prescribing patterns at non-ID and ID encounters. Future research exploring the reasons for differences in prescribing patterns between groups is recommended to clarify the meaning of these findings. However, taken together with other research on prescribing in people with ID, these results may indicate the need for GPs to review prescribing in patients with ID, with a focus on:
. correcting potential under-treatment of affective mental disorders in people with ID, including depression and anxiety;
. evaluating potential over-reliance on psychotropic medications for behavioural management (the NHS clinical guideline for medication use in populations with challenging behaviour may be a useful reference point for best practice Medication recommendations made by Australian GPs differ for people with ID and for controls. People with ID were recommended antipsychotics and anticonvulsant at higher rates, and had altered patterns of analgesic recommendations and lower rates of antihypertensive recommendations. Further research linking diagnostic and prescribing data would assist in clarifying reasons for prescribing in people with ID. Future active monitoring of medication recommendations in primary care is recommended to inform efforts to address the health status of people with ID. Monitoring may support targeted initiatives 3 including training, education, toolkits, and medicines reviews, thus improving prescribing practices among primary care providers. Administrative incentives to encourage proper assessment of complex cases 43 may also encourage proactive and preventative primary healthcare provision to this population.
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